- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2209–2232
of 17,848
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Neoplasms, Carcinoma, Renal Cell
- Interventions
- AG-013736 (axitinib)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • The Bronx, New York • Cleveland, Ohio + 2 more
- Conditions
- Refractory or Recurrent Solid Tumors, Excluding CNS Tumors
- Interventions
- Axitinib
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 17 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 17 more
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- Esketamine 56 mg, Esketamine 84 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more
- Conditions
- Stage 1 Hypertension, Stage 2 Hypertension
- Interventions
- Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 413
- States / cities
- Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
- Conditions
- Exostoses, Multiple Hereditary
- Interventions
- Palovarotene 2.5 mg, Palovarotene 5.0 mg, Placebo
- Drug · Other
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years to 14 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 9 more
- Conditions
- Cancer
- Interventions
- Patient Self-management
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- This Study is to Understand the Current Practice of Sodium Management in Acute Neurological Injury
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 17
- States / cities
- Hartford, Connecticut • New Haven, Connecticut • Miami, Florida + 13 more
- Conditions
- Breast Cancer
- Interventions
- herceptin, adriamycin, cyclophosphamide, taxol
- Biological · Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2019
- U.S. locations
- 141
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 119 more
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3), Endocrine Therapy
- Interventions
- Pharmacist delivered symptom monitoring and management
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Rochester, Minnesota • Madison, Wisconsin + 1 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011, Placebo
- Drug
- Lead sponsor
- Adare Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 51
- States / cities
- Chandler, Arizona • Tucson, Arizona • Sherwood, Arkansas + 45 more
- Conditions
- Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more
- Conditions
- Netherton Syndrome
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Rancho Santa Margarita, California • Chicago, Illinois • Philadelphia, Pennsylvania
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 29 more
- Conditions
- PTSD
- Interventions
- TNX-102 SL, Placebo
- Drug
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Placebo, cisplatin/carboplatin, onartuzumab, paclitaxel
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 34
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- DS-1062a, Docetaxel
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Anaheim, California • Glendale, California + 28 more
- Conditions
- HIV/AIDS, Gender, Behavior and Behavior Mechanisms
- Interventions
- Not listed
- Lead sponsor
- Hektoen Institute for Medical Research
- Other
- Eligibility
- 15 Years to 24 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Chicago, Illinois • Philadelphia, Pennsylvania
- Conditions
- Diabetic Retinopathy
- Interventions
- Fenofibrate, Placebo
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 66
- States / cities
- Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Molnupiravir, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,082 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 71
- States / cities
- Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more
- Conditions
- Kidney Transplantation
- Interventions
- FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Interventions
- Ancrod (Viprinex), Placebo
- Drug
- Lead sponsor
- Neurobiological Technologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Loma Linda, California + 48 more
- Conditions
- Chikungunya Virus Infection
- Interventions
- VLA1553
- Biological
- Lead sponsor
- Valneva Austria GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2031
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Hallandale, Florida • Chicago, Illinois + 7 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Needle core biopsies, Needle core biopsies of metastatic lesion
- Procedure
- Lead sponsor
- Jewish General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois